Body mass index also decreased more with semaglutide compared with placebo, with reductions of 1.5 kg/m versus 0.4 kg/m that were similar regardless of SGLT2i use at baseline ( P -interaction, 0.86)
What the Science Says According to the STEP 1 trial, which led to semaglutide's FDA approval for weight loss, participants who combined medication with increased physical activity lost significantly more weight
Lastly, cardiovascular benefits are critical
What are the symptoms of peripheral neuropathy
In 2020 about 13.7 million Medicare beneficiaries, around a quarter of the total, were diagnosed as overweight or obese, according to Juliette Cubanski and Tricia Neuman, researchers at KFF, a health information nonprofit that includes KFF Health News